{"nctId":"NCT05022004","briefTitle":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2021-12-20","type":"ACTUAL"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"count":599,"armGroups":[{"label":"BRIN-20-01","type":"EXPERIMENTAL","interventionNames":["Drug: Brinzolamide ophthalmic suspension"]},{"label":"Azopt®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azopt®"]}],"interventions":[{"name":"Brinzolamide ophthalmic suspension","otherNames":[]},{"name":"Azopt®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or nonpregnant female aged 18 years or older with chronic open angle glaucoma or ocular hypertension in both eyes.\n* Provide signed and dated informed consent in accordance with good clinical practice and local legislation prior to any study procedure.\n* Be able and willing to follow study instructions and complete all required visits.\n* Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n\nExclusion Criteria:\n\n* Subjects with angle closure glaucoma\n* Females who are pregnant, breast feeding, or planning a pregnancy.\n* Females of childbearing potential who do not agree to utilize an adequate form of contraception.\n* Current, or past history of, severe hepatic or renal impairment\n* Current, or history within 2 months prior to baseline of, significant ocular disease\n* Functionally significant visual field loss\n* Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy\n* Subjects currently in another clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups","description":"The recommended primary endpoint is the mean difference in Intraocular Pressure of both eyes between the two treatment groups at pre-specified time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.92","spread":"2.290"},{"groupId":"OG001","value":"25.06","spread":"2.363"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.87","spread":"2.378"},{"groupId":"OG001","value":"25.12","spread":"2.358"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.54","spread":"2.307"},{"groupId":"OG001","value":"24.83","spread":"2.389"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.52","spread":"2.423"},{"groupId":"OG001","value":"24.90","spread":"2.365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.87","spread":"3.436"},{"groupId":"OG001","value":"19.56","spread":"3.642"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.81","spread":"3.400"},{"groupId":"OG001","value":"19.62","spread":"3.423"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.87","spread":"3.544"},{"groupId":"OG001","value":"18.39","spread":"3.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.69","spread":"3.572"},{"groupId":"OG001","value":"18.47","spread":"3.468"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.86","spread":"3.162"},{"groupId":"OG001","value":"18.91","spread":"3.333"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.87","spread":"3.067"},{"groupId":"OG001","value":"18.99","spread":"3.123"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.76","spread":"3.252"},{"groupId":"OG001","value":"17.73","spread":"3.418"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.71","spread":"3.190"},{"groupId":"OG001","value":"17.70","spread":"3.162"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IOP of Both Eyes Between the 2 Treatment Groups.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.67","spread":"3.441"},{"groupId":"OG001","value":"-5.27","spread":"3.617"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.71","spread":"3.286"},{"groupId":"OG001","value":"-5.28","spread":"3.531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.68","spread":"3.475"},{"groupId":"OG001","value":"-6.44","spread":"3.717"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.82","spread":"3.484"},{"groupId":"OG001","value":"-6.43","spread":"3.630"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.68","spread":"3.290"},{"groupId":"OG001","value":"-5.92","spread":"3.577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.64","spread":"3.107"},{"groupId":"OG001","value":"-5.91","spread":"3.468"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.78","spread":"3.329"},{"groupId":"OG001","value":"-7.10","spread":"3.614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.81","spread":"3.239"},{"groupId":"OG001","value":"-7.20","spread":"3.500"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":297},"commonTop":["Dysgeusia","Vision Blurred","Foreign Body Sensation in Eyes","Headache","Conjunctival Hyperemia"]}}}